Mintiply Capital Offers 10% Stake In Premium International Injectable For Investors In Sri Lanka

Mintiply Capital, a recognized leader in investment banking with a focus on wealth management, private equity, venture capital, and advising on digital assets, has taken on the task of orchestrating the sale of a 10% equity share in "Premium International Injectable." This up-and-coming pharmaceutical entity, rooted in Sri Lanka, offers investors the prospect of owning a part of a venture that is set to significantly impact the local pharmaceutical landscape. Premium International Injectable specializes in the production of sterile liquid injectables, such as insulin, aiming to address the increasing health care demands within the region.

A standout feature of this investment opportunity is the company's 15-year Offtake Agreement with the State Pharmaceuticals Manufacturing Corporation (SPMC) of Sri Lanka. This arrangement guarantees a minimum purchase of roughly 75% of the company's output, securing a steady income and a dependable market for its product lineup.

Exploring the Market Landscape

The pharmaceutical market in Sri Lanka, where non-communicable diseases (NCDs) make up 90% of the health burden, showcases a pressing need for medicines aimed at diabetes, cardiovascular diseases, and respiratory issues. This backdrop forms a fertile ground for Premium International Injectable, whose revenue streams are estimated to span various pharmaceutical categories, with insulin making up 51%, cardiovascular treatments 17%, respiratory solutions 12%, and other products covering the remaining 20%.

Sri Lanka's pharmaceutical sector is on a trajectory to hit the $750 million mark by 2024, underscoring the growth prospects of the market. The country's heavy reliance on imported pharmaceuticals, which currently stands at about 85%, underscores a significant opportunity for local production units like Premium International Injectable to cater to the domestic demand.

The competitive cost structure of Sri Lanka, combined with its commitment to maintaining high-quality production standards, not only meets local healthcare needs but also opens up avenues for exporting to markets in South Asia and Africa. This enhances the attractiveness of investing in Premium International Injectable, as it promises diversified and potentially lucrative revenue streams.

Mintiply Capital's initiative to facilitate the sale of a stake in Premium International Injectable presents a compelling opportunity for investors. By capitalizing on Sri Lanka's burgeoning pharmaceutical market and the strategic partnership with SPMC, the investment promises stability and growth. The focus on producing essential medications like insulin and the potential for expanding into international markets further underscore the appeal of this venture, positioning it as a noteworthy contribution to Sri Lanka's healthcare sector.